KIT and gastrointestinal stromal tumor: Overall, our data indicate that KIT inhibitor treatment alone does not fully suppress MAPK signaling; residual PI3K signaling was also observed in the GIST-T1/10R cell lines, which might play a role in sustaining proliferation and survival in the presence of KIT inhibitors.